SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. Logo

SHIN NIPPON BIOMEDICAL LABORATORIES, LTD.

A contract research organization providing comprehensive drug development services.

2395 | T

Overview

Corporate Details

ISIN(s):
JP3379950003
LEI:
Country:
Japan
Address:
鹿児島市宮之浦町2438番地

Description

Shin Nippon Biomedical Laboratories, Ltd. (SNBL) is a contract research organization (CRO) providing comprehensive drug development services. Established in 1957 as Japan's first CRO, the company supports pharmaceutical clients throughout the development lifecycle, from preclinical safety studies to clinical trial management. SNBL offers a full suite of services, including safety assessments and clinical data management. A key area of innovation is its proprietary nasal drug delivery technology, SMART (Simple MucoAdhesive Release Technology). The company's mission is to contribute to medical advancement and alleviate patient suffering by supporting the creation of new pharmaceuticals.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-07 03:55
確認書
Japanese 10.9 KB
2025-11-07 03:47
半期報告書-第53期(2025/04/01-2026/03/31)
Japanese 255.3 KB
2025-06-30 08:58
臨時報告書
Japanese 24.7 KB
2025-06-27 07:46
確認書
Japanese 8.2 KB
2025-06-27 07:40
内部統制報告書-第52期(2024/04/01-2025/03/31)
Japanese 23.5 KB
2025-06-27 07:32
有価証券報告書-第52期(2024/04/01-2025/03/31)
Japanese 3.0 MB
2024-11-06 04:17
確認書
Japanese 10.8 KB
2024-11-06 04:11
半期報告書-第52期(2024/04/01-2025/03/31)
Japanese 253.7 KB
2024-06-26 04:52
臨時報告書
Japanese 24.6 KB
2024-06-25 07:06
確認書
Japanese 8.2 KB
2024-06-25 06:57
内部統制報告書-第51期(2023/04/01-2024/03/31)
Japanese 22.5 KB
2024-06-25 06:38
有価証券報告書-第51期(2023/04/01-2024/03/31)
Japanese 3.2 MB
2024-02-02 03:40
確認書
Japanese 10.8 KB
2024-02-02 03:39
四半期報告書-第51期第3四半期(2023/10/01-2023/12/31)
Japanese 203.9 KB
2023-11-07 07:18
確認書
Japanese 10.8 KB

Automate Your Workflow. Get a real-time feed of all SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for SHIN NIPPON BIOMEDICAL LABORATORIES, LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Evogene Ltd. Logo
A computational biology company using AI to develop life-science products.
Israel
EVGN
Evotec SE Logo
A life science company offering drug discovery and development partnership solutions.
Germany
EVT
EXICURE, INC. Logo
Early-stage biotech developing nucleic acid therapies based on SNA technology.
United States of America
XCUR
EyeGene,Inc Logo
Develops gene/cell therapies for age-related diseases and preventive vaccines.
South Korea
185490
Femtobiomed Inc. Logo
Develops a non-viral intracellular delivery platform for cell and gene therapy.
South Korea
327610
Develops AI data center campuses with co-located hybrid power generation.
United States of America
FRMI
Fluicell AB Logo
A biotech firm creating engineered tissues for regenerative medicine and drug development.
Sweden
FLUI
Foghorn Therapeutics Inc. Logo
Develops medicines targeting the chromatin regulatory system for oncology.
United States of America
FHTX
Fortrea Holdings Inc. Logo
A global CRO providing clinical development and patient access solutions to life sciences.
United States of America
FTRE
FUSION ANTIBODIES PLC Logo
CRO providing end-to-end services for preclinical antibody development.
United Kingdom
FAB

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.